thx for posting BK--is nice to hear tidbits straight from the top... lots in the hopper for sure. im personally expecting good news following the FDA meeting for Brilacidin Ph III. guess we'll hear more mid-July. some ABX reading. Antibiotics Not Given Same Research Attention as Rare Diseases, Says Report http://www.dddmag.com/news/2015/06/antibiotics-not-given-same-research-attention-rare-diseases-says-report Full Report (see pgs 13-23, good info inc ABX patents) NovaBiotics mentioned... has a similar MOA to HDP-M/Def Mimetics (synthetic/rationally-designed antimicrobial peptides... their tagline: "Taking Nature's Lead in Antimicrobials") http://www.marks-clerk.com/MarksClerk/media/MCMediaLib/PDF%27s/Reports/Life-Sciences-Report-2015-From-rare-to-routine.pdf NovaBiotics http://www.novabiotics.co.uk/technology